Life-cycle Approach to CMC Challenges and Opportunities
|
|
- Osborne McCormick
- 7 years ago
- Views:
Transcription
1 Life-cycle Approach to CMC Challenges and Opportunities Michael J James Ph.D. Director Global Regulatory Affairs GlaxoSmithKline 26th Annual EuroMeeting March 2014 ACV, Vienna Austria
2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
3 Contents Introduction Drivers for CMC Life-Cycle Management Expedited Development and Approval of Innovative Medicines Challenges Limited Regulatory Opportunities Future Opportunities Concluding Remarks 3
4 Life-cycle Management of CMC (1) CMC life-cycle management is becoming increasingly important due to a number of factors including: Globalisation of development and manufacture of pharmaceuticals Increased and diverse global regulatory expectations Supply chains becoming more complex Advances in technology Implementation of ICH Q8, Q9, Q10 and Q11 Environmental considerations Expedited development and approval timelines for innovative medicines 4
5 Life-cycle Management of CMC (2) Important technical drivers for change include: Manufacturing sustainability Manufacturing efficiencies (economic and environmental) Ensuring security of supply Response to regulatory developments Advances in manufacturing and control technology Commitment to continual improvement in quality 5
6 Expedited Development and Approval for Innovative Medicines (1) EMA Adaptive Licensing Initiative Introduces concept of staggered approval Also known as adaptive or progressive licensing Envisaged for situations not covered by conditional marketing authorisations Prospectively planned, adaptive approach to regulation of drugs through iterative phases of evidence gathering, followed by regulatory evaluation and license adaptation Balances timely access for patients with the need to provide adequate evolving information on benefits and harms 6
7 Expedited Development and Approval for Innovative Medicines (2) FDA Breakthrough Therapy Designation Intended to expedite development and review of drugs for serious or life-threatening conditions Manufacturing development process and capabilities will need to keep pace with clinical development Requires a well thought out CMC life-cycle plan which will need to encompass: Manufacturing process, capability, facilities and equipment Process validation - scale up and comparability Specifications Stability 7
8 Expedited Development and Approval for Innovative Medicines (3) These initiatives will have significant CMC impact if earlier access to patients is to be achieved How can iterative phases of evaluation of CMC data be managed effectively? A rolling review? What would a progressive license look like? Control Strategy - continually evolving Innovative manufacturing approaches may be needed e.g. continuous processing Appropriate stability data package Process validation ongoing verification Role for extended Post-approval change management protocol?? 8
9 Challenges The current system is challenging to industry and regulators (QbD) Submissions are becoming more complex Leading to more detail being submitted Potential for more information to become registered (compliance related) Still lack of clarity on what information is required and where it should be located May discourage transparency in regulatory filings 9
10 Challenges Different approaches in 3 ICH regions Variation categories (see next slide) Use of protocols to prospectively manage changes (EU and US) JNDA application form describes matters subject to approval Regulatory requirements of non-ich regions/countries even more diverse adds another level of complexity Often a checklist approach, rather than a science and risk based evaluation Complex, costly and resource intensive Hinders innovation and continual improvement 10
11 Variation Categories - EU, US and Japan Variation Category EU US Japan Major Type II Prior Approval Supplement (PAS) Partial Change Approval Application Moderate Type IB Change-Being- Effected-in-30-Days (CBE-30) Minor Type IAIN Type IAAR Change-Being- Effected (CBE-0) Annual Report Minor Partial Change Notification 11
12 Limited Regulatory Opportunities (1) ICH Implementation of Q8, Q9, Q10 (and Q11) Demonstrate effective pharmaceutical quality system, and product and process understanding, including the application of quality risk management principles Opportunity to: Optimise science and risk based post-approval change processes to maximise benefits from innovation and continual improvement Provides opportunities for a more science and risk based approach to assessing changes across the life cycle But have these opportunities and benefits been fully realised? 12
13 Limited Regulatory Opportunities (2) EU Revision to EU Variations Regulation To establish a simpler, clearer and more flexible legal framework To adapt to the ICH new quality concepts Q8, Q9 and Q10 Commission Public Consultation Paper (Oct 2007) Introduced the concept of Design Space Acknowledged that continuous improvement of manufacture should be supported, e.g. by providing further flexibility to manufacturers who have undertaken the efforts to put in place quality tools 13
14 Limited Regulatory Opportunities (3) EU Commission Variations Classification Guideline (Jan 2010) Included variations for the introduction of a new design space or extension of an approved design space Changes to non-cpp Type II variation by default Introduced variation categories for a post approval change management protocol Questions and answers on post approval change management protocols (Mar 2012) Commission Variations Classification Guideline (revised May 2013) No significant changes for CMC aspects Ongoing dialogue needed 14
15 Limited Regulatory Opportunities (4) US FDA s CMC Post-approval Management Plan (CMC- PMP) proposals Provides clarity on regulatory commitment Facilitates product lifecycle management Demonstrated product/process understanding and controls could lead to significant reduction of postapproval manufacturing supplements Utilize Existing Regulatory Framework 21 CFR (CMC Submission for DS and DP) 21 CFR (Post-approval changes) Initial progress followed by implementation stoppage 15
16 Limited Regulatory Opportunities (5) US Comparability Protocols for Approved Drugs: Chemistry, Manufacturing, and Controls Information (Draft, Feb 2003) CMC Post-approval Manufacturing Changes to be documented in Annual Reports (Final, Mar 2014) Down regulation of some low risk CMC changes from CBE-30 and CBE-0 to annual report Specified Biotechnology and Specified Biological Products Annual Report (Planned draft, 2014) Comparability Protocols for Approved Drugs: CMC information (Planned draft, 2014) FDA is exploring regulatory commitments 16
17 Optimised Regulatory Framework (1) The following components are considered necessary to establish an optimised framework to effectively manage the life cycle of CMC: Clear definition of regulatory commitments for manufacture and control in the regulatory submission Identification of these regulatory commitments from development data, required by the assessor to carry out initial review Regulatory commitments would provide basis for compliance and change management across the life-cycle 17
18 Optimised Regulatory Framework (2) Clear presentation of operational flexibility proposed by the applicant for approval by the authorities Removes any ambiguity about what that has been approved Increased role of the control strategy to facilitate compliance across the life-cycle Harmonized approach on technical requirements to assess manufacturing changes Technical criteria should consider risks, development knowledge, manufacturing history and impact of change on quality (CQAs and control strategy) 18
19 Optimised Regulatory Framework (3) Opportunity for some low risk CMC changes to be managed as part of a robust change management system within a Company s Pharmaceutical Quality System Expanded use of post-approval change management protocols to prospectively manage complex CMC/QbD changes across the life-cycle Support continual improvement for QbD submissions Enable multiple changes in a single protocol (where acceptance criteria are relevant) Role for extended protocol? 19
20 Concluding Remarks The life-cycle management of CMC is becoming increasingly important to industry, regulators and patients, as a result of several factors, including: Continual improvement and innovation Expedited development and approval of innovative medicines QbD implementation The current regulatory system is challenging to both industry and regulators The new ICH quality guidelines and regional regulatory initiatives provide only marginal benefits However elements of these could be used as building blocks for future system 20
21 Concluding Remarks Ideally, ICH harmonized guideline on Life-Cycle Management of CMC developed Clear definition of regulatory commitments More extended application of post-approval change management protocols Agreement on technical requirements to assess manufacturing changes But also opportunities in Europe for More flexible use of PACM Protocols Management of changes to non-cpps (within a Design Space) with appropriate level of regulatory oversight Future revisions to the Variations Classifications guideline 21
22 Thank you for your attention Any questions??? 22
Post-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationAn FDA Perspective on Post- Approval Change Management for PAT and RTRT
An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes
More informationLifecycle CMC Management: ICH Q12 Progress to date
Lifecycle CMC Management: ICH Q12 Progress to date BWP/QWP/GMDP IWG Industry European workshop 28-29 October 2015 Jean-Louis ROBERT (EU) Graham Cook (EFPIA) Please take note The following slides represent
More informationIntroduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
More informationQuality Considerations for Breakthrough Therapies-FDA Perspective
Quality Considerations for Breakthrough Therapies-FDA Perspective DIA June 17, 2014 Ramesh K. Sood, Ph.D. Acting Division Director and Angelica Dorantes, Ph.D. xxx ONDQA/OPS/CDER/FDA 1 Background Outline
More informationQbD Considerations for Analytical Methods - FDA Perspective
QbD Considerations for Analytical Methods - FDA Perspective IFPAC Annual Meeting Baltimore, January 25, 2013 Sharmista Chatterjee, Ph.D. CMC Lead for QbD ONDQA/CDER/FDA Outline Role of analytics in drug
More informationICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance
ICH Public Meeting October 2, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance The Current State of Pharmaceutical Manufacturing Inability to predict
More informationICH Q10 Pharmaceutical Quality System (PQS)
ICH Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Q10 PQS Guideline Background Objectives
More informationHow Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program
How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program Presenter: Jan Holladay Pierre, MPH Quality Principal Leader DynPort Vaccine Company LLC, A CSC Company This presentation
More informationFostering Further Collaboration between PMDA and Applicants with Efficient Project Management in Drug Development
Fostering Further Collaboration between PMDA and Applicants with Efficient Project Management in Drug Development Kazuishi Sekino Review Director Office of New Drug I Pharmaceuticals & Medical Devices
More informationICH Q10 and Change Management: Enabling Quality Improvement
ICH Q10 and Change Management: Enabling Quality Improvement Bernadette Doyle PhD Vice President and Head of Global Technical Group Global Manufacturing and Supply GlaxoSmithKline Overview Drivers for Change
More informationThe Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche,
More informationQuestions and answers on post approval change management protocols
30 March 2012 EMA/CHMP/CVMP/QWP/586330/2010 Committee for Medicinal Products for Human Use (CHMP) Questions and answers on post approval change management protocols Draft agreed by CHMP / CVMP Quality
More informationChanges to an Approved Product
Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved
More informationStakeholders identification: key success factor for the implementation of Electronic Document Management Systems
Stakeholders identification: key success factor for the implementation of Electronic Document Management Systems Isabel Saez-Pujol Director, Informatics & Knowledge Management Daiichi Sankyo Development,
More informationPHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
More informationGMP/Regulatory Environment in the
GMP/Regulatory Environment in the Latin America Irene Ortiz Barreal, Pharm. D., R.Ph. Pfizer International Affiliate Quality Compliance Regional Leader Latin America/Caribbean April 14, 2011 Discloser
More informationCDISC standards and data management The essential elements for Advanced Review with Electronic Data
Session 6: Toward Electronic Submission of Study Data for New Drug Applications CDISC standards and data management The essential elements for Advanced Review with Electronic Data Yuki Ando Senior Scientist
More informationRisk-Based Change Management Using QbD Principles
Risk-Based Change Management Using QbD Principles Lynne Krummen, Ph.D. VP, Global Head, Technical Regulatory Biologics Genentech, a member of the Roche Group CMC Forum 2013 Tokyo, Japan Presentation Outline
More informationBenefits and Challenges of Change Protocol Approach: An EU Agency Perspective
Benefits and Challenges of Change Protocol Approach: An EU Agency Perspective Ann Johnsson, Senior Expert Medical Products Agency (MPA), Uppsala, Sweden Post Approval Change Management Protocols (PACMPs)
More informationICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
More informationSTOPPERS PREFILLABLE SYRINGE PLUNGERS. The New Definition of High-Quality Components
STOPPERS PREFILLABLE SYRINGE PLUNGERS The New Definition of High-Quality Components Proactively Partnering to Science and Technology West has adopted a continuous verification process that is unrivaled
More informationWorkshop A Design Space (DS)
Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information
More informationQuality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party
Quality by Design Application and Perspectives for biologicals K. Ho, CHMP Biologics Working Party Pharmaceutical development (Q8) Aim: To design a quality product and a manufacturing process to consistently
More informationISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Disclaimer
ISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Vada Perkins, CAPT, USPHS US Food and Drug Administration/ Center for Biologics Evaluation and Research 11 October
More informationProduct Quality Management
Product Quality Management Deborah Baly, Ph.D Sr. Director, Commercial Product Quality Management, GNE/ROCHE 1 Presentation Outline: Product Quality Management Regulatory landscape and need for integrated
More informationBreakthrough Therapy Program U.S. Food and Drug Administration (FDA)
Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Presentation before the European Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP) Jarilyn Dupont,
More informationQuality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
More informationTransatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth
Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth 1 About EFPIA Þ EFPIA is the voice of the European innovative pharmaceutical industry,
More informationTarget Product Profile (TPP) Process. Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company
Target Product Profile (TPP) Process Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company 1 Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationQuality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011
Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical
More informationICD-9-CM to MedDRA Mapping How Well Do the. Disclaimer
ICD-9-CM to MedDRA Mapping How Well Do the Two Terminologies Correlate Anna Zhao-Wong, MD, PhD Deputy Director MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides
More information2009 Life Sciences Industry Document Management/Collaboration Survey. DIA Disclaimer. 2009 Benchmark / Survey Objectives
2009 Life Sciences Industry Document Management/Collaboration Survey Conducted and Prepared by International Life Science Solutions & Associates 10 th EU EDM Meeting Vienna, Austria, 2009 DIA Disclaimer
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More informationTopic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW. Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo
Topic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo Introduction to Speakers John Duan, Clinical Pharmacology & Biopharmaceutics Reviewer,
More informationGuidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
More informationQuestions and answers on post approval change management protocols
27 October 2010 EMA/CHMP/CVMP/QWP/586330/2010 Questions and answers on post approval change management protocols Draft Draft Agreed by QWP September 2010 Adoption by CHMP for release for consultation 23
More informationSafety Risk Assessment in Drug Development
Safety Risk Assessment in Drug Development The LA Regional Experience Terezinha C. Teotonio, RN, MSN PPD LA PVG Manager Lessons Learned Globally Need for testing prior to marketing Need for regulations
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationA CRO's Dilemma - The CDMS Validation Package that Failed Client Audits 19.OCT.2009 1. Disclaimer
A CRO's Dilemma - The CDMS Validation Package that Failed Client Audits Teri Stokes, Ph.D., Director GXP International Concord, MA - USA Common Sense Computer Validation 19.OCT.2009 1 Disclaimer The views
More informationManaging Clinical Operations Risks. Lars Schmiedeberg
Managing Clinical Operations Risks Lars Schmiedeberg Disclaimer The views and opinion expressed in this slides are that of the presenter and do not necessarily reflect the views and opinions of ii4sm ltd.
More informationGuidance for Industry: Quality Risk Management
Guidance for Industry: Quality Risk Management Version 1.0 Drug Office Department of Health Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. What is risk?... 4 5. Integrating
More informationFinal Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed by the ICH SC on 10 November 2005
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Final Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationtraining programme in pharmaceutical medicine Regulatory affairs
training programme in pharmaceutical medicine Regulatory affairs INFARMED, Lisbon 19-21 january 2012 Regulatory affairs 19 21 january 2012 LocaL: INFARMED, Lisbon curricular unit Leader: Hélder Mota Filipe,
More informationAdventist HealthCare, Inc.
IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human
More informationCHANGE MANAGEMENT. Overseeing and Empowering How to Achieve Balance?
CHANGE MANAGEMENT Overseeing and Empowering How to Achieve Balance? Problem Statement Change management is not visible to regulatory assessors Change management is part of the PQS and the process is not
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationQuality by Design (QbD) Overview
Quality by Design (QbD) Overview Gary Warren Director, Haemostasis and Thrombosis R&D October, 2015 CSL Behring Pty Ltd Broadmeadows, Victoria What is Quality by Design (QbD)? QbD is: A Quality System
More informationIndustry Implications of Pharmaceutical Quality ICH Guidelines
EIPG General Assembly Industry Implications of Pharmaceutical Quality ICH Guidelines 20 th April 2008 Pharmaceutical Quality Develop a harmonised pharmaceutical quality system applicable across the lifecycle
More informationCertification for Data Managers- How high is the bar?
Certification for Data Managers- How high is the bar? Linda M. Talley, CCDM International Network of Clinical Data Management Associations-(INCDMA) Chair Society for Clinical Data Management (SCDM)- Chair
More informationProcess Validation: Practical Aspects of the New FDA Guidance
Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory
More information100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS
100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS Mr. R.M. Gupta (M. Pharm.), is a free lancer consultant for US DMF, COS, ANDA, ACTD, CTD, ectd and he is also the director of
More informationHTA and Post-Launch Studies
EXPLORING THE FUTURE OF RE FOR DRUGS IN EUROPE ELEMENTS AFFECTING THE FUTURE OF RE IN EUROPE? Baseline factors Payers continue to face austerity pressures Decision making by Payer / HTA bodies remains
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationSage ERP I White Paper
The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness
More informationFDA's Module 1 Update: From Ideas to Implementation. Jared C. Lantzy, PMP
FDA's Module 1 Update: From Ideas to Implementation Jared C. Lantzy, PMP The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationEmergence of Compassionate Use programmes
Emergence of Compassionate Use programmes Rosanna Melchior, PharmD, MS IDRAC, Thomson Scientific Overview What is compassionate use (CU) Overview of CU in Europe Authorities and Sponsors Roles and Responsibilities
More informationMoving from Quality Control to Quality Assurance (Proactive Compliance!)
Moving from Quality Control to Quality Assurance (Proactive Compliance!) Guy Wingate, VP & Compliance Officer Global Manufacturing & Supply, GlaxoSmithKline Disclaimer The views and opinions expressed
More informationWhite paper: FDA Guidance for Industry Update Process Validation
White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,
More informationElectronic Health Records for Clinical Research. EHR Compliant to Clinical Trial Requirements. Oct 2009 1. Disclaimer
Electronic Health Records for Clinical EHR Compliant to Clinical Trial Requirements Mathias Poensgen EHRCR project / Aris Global Oct 2009 1 Disclaimer The views and opinions expressed in the following
More informationOur name ASPHALION derives from the Greek word asphaléia, alluding to values such as firmness, stability, certainty and reliability.
Company Profile Our History ASPHALION is an International Drug Development and Regulatory Affairs consultancy firm founded in 2000, with an international team of over 40 people. Our Values Our name ASPHALION
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationThe Main Challenges around IDMP 1 and Ways to Solve Them. Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany
The Main Challenges around IDMP 1 and Ways to Solve Them Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany Abstract: As of 1 July 2016, pharmaceutical companies which develop and
More informationICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
More informationRegulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG
Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory
More informationQuality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
More informationTaking a Leap Toward Global Supply Chain Efficiency
Taking a Leap Toward Global Supply Chain Efficiency 2 Taking a Leap Toward Global Supply Chain Efficiency INTRODUCTION PROBLEM STATEMENT Pharmaceutical manufacturers face a number of challenges to produce
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationRegulatory strategies for small companies /SMEs
TOPRA Module 1 Strategic planning in RA Regulatory strategies for small companies /SMEs A presentation by Ineke Jonker-Hoogerkamp, Director Regulatory Affairs Neurology, Genzyme Europe BV Learning Outcomes
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationPHARMACEUTICAL REFERENCE STANDARDS
PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,
More informationICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
More informationWorkshop on process validation
Workshop on process validation CMC Strategy Forum Europe 2013 EBE Process validation satellite session Pragues, 06/05/2013 Kowid Ho Scope / background Process evaluation/validation of biotechnology derived
More information298.015) UC 6:30 8:20 PM
Course Description: This course is an in depth review of the history, authorizing statute and regulatory authority of US FDA and the influence and impact of FDA on science and health policy. Drug development,
More informationRegulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare Applications
More informationGlobal regulatory affairs role in the biopharmaceutical industry
CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global
More informationEFPIA Principles for the Development of the EU Clinical Trials Portal and Database
Position Paper EFPIA Principles for the Development of the EU Clinical Trials Portal and Database Executive summary EFPIA sees the implementation of the Clinical Trials Regulation 1 as an opportunity to
More informationWorkshop on process validation
Workshop on process validation General concepts on process validation Kowid Ho Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture
More informationRe: Docket No. FDA 2013 D 0575: Draft Guidance for Industry on Expedited Programs for Serious Conditions Drugs and Biologics; Availability
August 26, 2013 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013 D 0575: Draft Guidance for Industry on Expedited
More informationWork plan for GMP/GDP Inspectors Working Group for 2016
21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016
More informationThe Role of the CRO in Effective Risk-Based Monitoring
New Whitepaper The Role of the CRO in Effective Risk-Based Monitoring The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging
More informationPharmaceutical Quality & Clinical Research Quality: The Interaction
4 th Jerusalem Conference: Quality by Design (QbD)) & Pharma Sciences, May 20-22, 2014 The Edmund Safra Campus, The Hebrew University of Jerusalem Pharmaceutical Quality & Clinical Research Quality: The
More informationGuideline on Process Validation
1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /
More informationG. Recalls. http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm.
G. Recalls 1. Background When an FDA-regulated product is defective, potentially harmful, or mislabeled, recalling that product removing it from the market or correcting the problem is often the most effective
More informationUNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES
UNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES A WHITE PAPER ON THE REQUIREMENTS, REGULATIONS AND OPPORTUNITIES CONTAINED IN EC DIRECTIVE 98/79/EC AND A BRIEF COMPARISON
More informationHow Transparent are Regulatory Agencies with regard to Review Timelines? Disclaimer
How Transparent are Regulatory Agencies with regard to Review Timelines? A Global Review Rosanna Melchior Sr Manager, Reg.Intelligence THOMSON REUTERS, France Disclaimer The views and opinions expressed
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationDisclaimer. www.diahome.org
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors,
More informationHistory and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationRAPS ONLINE UNIVERSITY
RAPS ONLINE UNIVERSITY Practical education and training for business success. For regulatory professionals, there is only one name to know and trust for online education and training RAPS Online University.
More informationBy Natalia Wilson, MD, MPH
White Paper The value of unique device identification across healthcare By Natalia Wilson, MD, MPH Executive summary The Unique Device Identification (UDI) System Proposed Rule was published by the U.S.
More informationPharmaceutical Engineering: The Lisbon Masters Program
EAFP Catania June 24-26, 26, 2010 Pharmaceutical Engineering: The Lisbon Masters Program José Menezes, Rogério Gaspar, João Bordado,, José Morais Technical University of Lisbon (Portugal) Faculty of Pharmacy,
More informationEmerging Device Topics for Regulatory Consideration.. Janine Jamieson May 2015
Emerging Device Topics for Regulatory Consideration. Janine Jamieson May 2015 Disclaimer These are my personal views and not necessarily those of MHRA as an organisation. 2 European regulation of combination
More informationGuidance for Industry: Starting Material Supplier Management
Guidance for Industry: Starting Material Supplier Management Version 1.0 Drug Office Department of Health. Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. Selecting and
More informationKey considerations for outsourcing late phase clinical research
Key considerations for outsourcing late phase clinical research Alan Nelson (on behalf of Van Zyl Engelbrecht) Senior Project Director at UBC: An Express Script Company Layout of presentation My presentation
More informationAnalysis One Code Desc. Transaction Amount. Fiscal Period
Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00
More information